Evidence mapPaperPMID 41501789Full record

ReviewMolecular cancer2026

Metabolic characteristics in hepatocellular carcinoma: amino acid metabolic reprogramming.

Ran Zhou, Yuejun Li, Guanghui Li, Yan Li, Lie Luo, Bin Wang, Liping Wang

Abstract readReview
In one paragraph

Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ran ZhouDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China.
Yuejun LiDepartment of Stomatology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Guanghui LiDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China.
Yan LiDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China.
Lie LuoDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China.
Bin WangDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China. wangbin@huashan.org.cn.
Liping WangDepartment of Pharmacy, Jing'an District Central Hospital of Shanghai, Fudan University, Shanghai, 200040, China. lpwang14@fudan.edu.cn.

Funding

2023 Shanghai "Rising Stars of Medical Talents" Youth Development Program Youth Medical Talents-Clinical Pharmacist ProgramJing'an District Discipline Construction Project (Key Discipline) 2024ZD01Jing'an District Excellent Youth Program of the Health System 2024YQ02Jing'an District Health Research Project 2019QN02National Natural Science Foundation of China 82003924
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a common type of primary liver cancer and is considered the third leading cause of cancer-related deaths worldwide. The high aggressiveness and resistance to therapies exhibited by HCC present significant challenges to global public health. As the primary metabolic organ in the human body, the liver undergoes substantial metabolic reprogramming during carcinogenesis, affecting various metabolic pathways including those involved in carbohydrates, lipids, and amino acids. Notably, disruptions in amino acid metabolism play a critical role in the initiation and progression of HCC, helping to sustain its malignant characteristics. This review aims to provide an in-depth analysis of the alterations observed in aromatic amino acids metabolism, branched chain amino acids (BCAAs) metabolism, glutamine metabolism, and other amino acid metabolism processes, including serine, arginine, and methionine, along with the expression patterns of associated metabolic enzymes. Furthermore, it discusses potential therapeutic approaches and their clinical relevance, offering insights and strategies for improving HCC diagnosis and treatment in the future.

Indexed as

Amino AcidsCarcinoma, HepatocellularLiver NeoplasmsMetabolic ReprogrammingAnimalsHumansMetabolic Networks and PathwaysAmino AcidsAmino acid metabolismHepatocellular carcinomaMetabolic reprogramming

Identifiers

PMID41501789
PMCPMC12882192

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.